Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia
Latest Information Update: 14 Jul 2022
At a glance
- Drugs Opaganib (Primary)
- Indications COVID-19 pneumonia
- Focus Proof of concept; Therapeutic Use
- Sponsors RedHill Biopharma
Most Recent Events
- 12 Jul 2022 According to a RedHill Biopharma media release, data from this study published in Open Forum Infectious Diseases.
- 07 Sep 2021 According to a RedHill Biopharma media release, data from the study has been recently published in medRxiv.
- 24 Jun 2021 Results presented at the World Microbe Forum 2021